Christopher Rozell highlighted the impact of the NIH program, including work with collaborators at Emory and Mt. Sinai that identified a biomarker of disease recovery for patients with treatment-resistant depression.
Blank Space (small)
(text and background only visible when logged in)
(text and background only visible when logged in)